tetano
Editor, Senior Moderator
Viruses. 2015 Jul 13;7(7):3835-3856.
[h=1]Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems.[/h] Trevisan M[SUP]1[/SUP], Sinigaglia A[SUP]2[/SUP], Desole G[SUP]3[/SUP], Berto A[SUP]4[/SUP], Pacenti M[SUP]5[/SUP], Pal? G[SUP]6,[/SUP][SUP]5[/SUP], Barzon L[SUP]7,[/SUP][SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The recent biotechnology breakthrough of cell reprogramming and generation of induced pluripotent stem cells (iPSCs), which has revolutionized the approaches to study the mechanisms of human diseases and to test new drugs, can be exploited to generate patient-specific models for the investigation of host-pathogen interactions and to develop new antimicrobial and antiviral therapies. Applications of iPSC technology to the study of viral infections in humans have included in vitro modeling of viral infections of neural, liver, and cardiac cells; modeling of human genetic susceptibility to severe viral infectious diseases, such as encephalitis and severe influenza; genetic engineering and genome editing of patient-specific iPSC-derived cells to confer antiviral resistance.
[h=4]KEYWORDS:[/h] CRISPR/Cas9; antiviral resistance; genetic susceptibility; genome editing; hepatitis C virus; human immunodeficiency virus; human induced pluripotent stem cells; patient-specific disease model; personalized therapy; viral infection
PMID: 26184286 [PubMed - as supplied by publisher] Free full text
[h=1]Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems.[/h] Trevisan M[SUP]1[/SUP], Sinigaglia A[SUP]2[/SUP], Desole G[SUP]3[/SUP], Berto A[SUP]4[/SUP], Pacenti M[SUP]5[/SUP], Pal? G[SUP]6,[/SUP][SUP]5[/SUP], Barzon L[SUP]7,[/SUP][SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The recent biotechnology breakthrough of cell reprogramming and generation of induced pluripotent stem cells (iPSCs), which has revolutionized the approaches to study the mechanisms of human diseases and to test new drugs, can be exploited to generate patient-specific models for the investigation of host-pathogen interactions and to develop new antimicrobial and antiviral therapies. Applications of iPSC technology to the study of viral infections in humans have included in vitro modeling of viral infections of neural, liver, and cardiac cells; modeling of human genetic susceptibility to severe viral infectious diseases, such as encephalitis and severe influenza; genetic engineering and genome editing of patient-specific iPSC-derived cells to confer antiviral resistance.
[h=4]KEYWORDS:[/h] CRISPR/Cas9; antiviral resistance; genetic susceptibility; genome editing; hepatitis C virus; human immunodeficiency virus; human induced pluripotent stem cells; patient-specific disease model; personalized therapy; viral infection
PMID: 26184286 [PubMed - as supplied by publisher] Free full text